Americans are using more prescription drugs than ever. Consequently, they’re coping with more side effects, drug interactions, and costs, especially if they’re using multiple medications. Kaiser Permanente Washington Health Research Institute (KPWHRI) scientists are on the forefront of answering questions about these concerns. We’re studying the beneficial and harmful effects of medications in real-world settings, and innovating better ways to manage and monitor drug use.
The institute contributes to national initiatives to monitor medication safety as well as providing information to help doctors and patients weigh the risks and benefits of various prescription drugs.
Funders of KPWHRI medication use and patient safety research include the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, the National Institutes of Health, the Patient-Centered Outcomes Research Institute, and other sources. A few projects include:
Brown JS, Kulldorff M, Petronis KR, Reynolds R, Chan KA, Davis RL, Graham D, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations. Pharmacoepidemiol Drug Saf. 2009;18(3):226-34. PubMed
Shannon SE, Foglia MB, Hardy M, Gallagher TH. Disclosing errors to patients: perspectives of registered nurses. Jt Comm J Qual Patient Saf. 2009 Jan;35(1):5-12. PubMed
Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ. 2009;338:b2137. doi: 10.1136/bmj.b2137. PubMed
Yu O, Boudreau DM, Buist DS, Miglioretti DL. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control. 2009 Jul;20(5):609-16. Epub 2008 Nov 30. PubMed
Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300(20):2417-9. PubMed
Sascha Dublin, MD, PhDSenior Investigator |
Jessica Chubak, PhDSenior Investigator |
Andrea J. Cook, PhDSenior Biostatistics Investigator |
Rita Mangione-Smith, MD, MPHExecutive Director and Senior Investigator, KPWHRI; Vice President for Research and Health Care Innovation, Kaiser Permanente Washington |
Jennifer C. Nelson, PhDDirector, Biostatistics; Senior Investigator |
David E. Arterburn, MD, MPHSenior Investigator |
Susan M. Shortreed, PhDSenior Biostatistics Investigator |
Lisa A. Jackson, MD, MPHSenior Investigator |
Karen Wernli, PhDSenior Investigator |
Onchee Yu, MSPrincipal Collaborative Biostatistician |
Rod L. Walker, MSPrincipal Collaborative Biostatistician |
Robert D. Wellman, MSPrincipal Collaborative Biostatistician |
Gaia Pocobelli, PhDSenior Collaborative Scientist |
Laura Harrington, PhD, MPHAssistant Investigator |
Jennifer F. Bobb, PhDAssociate Biostatistics Investigator |
Weiwei Zhu, MSSenior Collaborative Biostatistician |
Paige D. Wartko, PhD, MPHSenior Collaborative Scientist |
Maricela Cruz, PhDAssistant Biostatistics Investigator |
Brian D. Williamson, PhDAssistant Biostatistics Investigator |
Noorie Hyun, PhDAssociate Biostatistics Investigator |
Laurel Hansell, MA, MPHCollaborative Scientist |
Jess Mogk, MPHCollaborative Scientist |
Annie Piccorelli, PhDSenior Collaborative Biostatistician |
Susan Heckbert, MD, PhD
University of Washington (UW) Department of Epidemiology; UW Cardiovascular Health Research Unit
David Siscovick, MD, MPH
UW Department of Medicine; UW Department of Epidemiology; UW Cardiovascular Health Research Unit
Leslie Spangler, PhD
Amgen